Covidien, St. Louis, has won approval from the US Food and Drug Administration (FDA) for Covidien Imaging Solutions’ contrast delivery system with radio-frequency identification (RFID) technology.

The components integrate novel RFID technology to create a system that is designed to enhance patient safety by reducing the risk of medical errors in radiology departments. 

Covidien’s contrast delivery system combines its unit-dose Ultraject prefilled contrast media syringes with its Optivantage DH power injectors to provide the only RFID-enabled contrast delivery solution available in North America. RFID is an automatic identification technology that captures, stores and transmits data between the Ultraject syringe and the Optivantage DH power injector using devices called RFID transponders, or tags.